N2OFF Announcing Corporate Rebranding as Nexentis Technologies - Innovative AI and Data Driven Computational Biotech Company
Rhea-AI Summary
Nexentis Technologies (NASDAQ:NXTS) is the new identity for N2OFF, effective February 26, 2026, reflecting a strategic pivot from cleantech to computational biotech. The company completed acquisition of MitoCareX on October 20, 2025 and is integrating the MITOLINE™ discovery engine to advance mitochondrial carrier‑targeted oncology and inflammatory metabolic programs.
Nexentis will keep RTB solar assets as non‑core, value‑optimizing holdings while prioritizing preclinical discovery, lead optimization and partner engagement.
Positive
- MitoCareX acquisition closed on October 20, 2025
- Trading symbol change to NXTS effective February 26, 2026
- MITOLINE preliminary in vitro candidates showed anti‑tumor and anti‑inflammatory signals
Negative
- Programs preclinical — in vivo validation and clinical entry still pending
- Non‑core solar assets retained could distract capital allocation
News Market Reaction – NITO
On the day this news was published, NITO gained 38.64%, reflecting a significant positive market reaction. Argus tracked a peak move of +33.7% during that session. Our momentum scanner triggered 21 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $981K to the company's valuation, bringing the market cap to $4M at that time. Trading volume was exceptionally heavy at 9.6x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Sector peers show mixed moves: SEED and BIOX are up, ENFY and AVD are down, and SANW is flat. Momentum scanner flags SEED up 5.56% and BGLC down 5.14%, without a clear, unified sector direction. With NITO’s move at -0.15% and low volume, the rebranding appears stock-specific rather than a broad Agricultural Inputs sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 12 | In vitro data update | Positive | -13.5% | Subsidiary MitoCareX reported MITOLINE™ small molecules reduced pro-inflammatory markers. |
| Feb 02 | Research highlight | Positive | -7.1% | Company highlighted spaceflight-focused SLC25 carrier research aligned with MITOLINE™ platform. |
| Jan 22 | Positive in vitro results | Positive | +9.7% | MitoCareX reported preliminary MITOLINE™ data and plans to advance candidates preclinically. |
| Jan 15 | Spaceflight stress study | Positive | +5.4% | Spotlight on peer-reviewed SLC25 carrier research in microgravity and space stress conditions. |
| Jan 05 | Solar project economics | Positive | +0.0% | Company advanced $340,000 for better Flag solar project terms and higher profit stake. |
Recent biotech-focused news often drew sharp but inconsistent reactions, with both rallies and selloffs following positive scientific updates.
Over the past few months, N2OFF (NITO) has shifted from cleantech and solar toward a biotech identity anchored in MitoCareX and its MITOLINE™ platform. Multiple releases since Jan 2026 highlighted positive in vitro anti-inflammatory data and peer‑reviewed research on mitochondrial SLC25 carriers, yet market reactions were mixed, ranging from -13.47% to +9.7%. A January solar portfolio update involving a $340,000 payment for better project economics drew no price change. Today’s AI and computational biotech rebranding builds on this ongoing strategic pivot toward precision oncology and inflammatory metabolic diseases.
Market Pulse Summary
The stock surged +38.6% in the session following this news. A strong positive reaction aligns with management’s effort to clarify N2OFF’s transformation into Nexentis, an AI and data-driven computational biotech focused on mitochondrial carriers. The stock previously reacted sharply to MitoCareX news, with moves from -13.47% to +9.7% on scientific updates. With shares at $0.88, far below the $29.4 52-week high and $5.56 200-day MA, investors would still need to consider funding risks flagged in prior filings and the early-stage nature of the pipeline.
Key Terms
slc25 medical
in vitro medical
in vivo medical
precision oncology medical
small‑molecule medical
computational biotech technical
virtual screening technical
AI-generated analysis. Not financial advice.
New identity reflects Company’s evolution into an innovative data driven biotech company leveraging MITOLINE™ and mitochondrial carrier biology across oncology and inflammatory metabolic diseases
Neve Yarak, Israel, Feb. 25, 2026 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ: NITO) (“N2OFF” and the “Company”), a drug discovery company that is also investing in solar energy assets based on the RTB (Ready to Build) business model, today announced a comprehensive corporate rebranding to Nexentis Technologies Inc. (“Nexentis”) and change in the trading symbol of the Company to “NXTS” on the Nasdaq Capital Market. The name change and the symbol change will take effect on the Nasdaq Capital Market on February 26, 2026.
The new name and brand are designed to reflect the Company’s transformation into an innovative AI and data‑driven computational biotech platform focused on mitochondrial biology, precision oncology and inflammatory metabolic diseases.
At the core of this rebranding is the integration and scaling of MitoCareX Bio Ltd. (“MitoCareX”), now a wholly‑owned subsidiary of the Company, which brings a proprietary discovery engine targeting the mitochondrial SLC25 carrier family using its MITOLINE™ algorithm and structure‑guided virtual screening workflows. Nexentis intends to harness this platform to build a diversified pipeline of first‑in‑class small‑molecule programs, while continuing to selectively manage its RTB solar energy investments as a non‑core, value‑optimizing asset base.
The rebranding follows a strategic process and a series of recent milestones that have repositioned the Company:
- Closing of MitoCareX acquisition and strategic pivot to biotech: On October 20, 2025, N2OFF completed the acquisition of MitoCareX, a biotechnology company focused on drug discovery for resistant cancers and inflammatory metabolic disease indications through targeting the mitochondrial SLC25 protein family, with MitoCareX becoming a wholly‑owned subsidiary. The transaction marked a deliberate expansion from cleantech into biotechnology and established the foundation for the Company’s drug discovery and development‑focused strategy.
- Validation of the MITOLINE™ discovery platform: MitoCareX has generated multiple rounds of in vitro data using its MITOLINE™‑powered discovery engine, including earlier studies demonstrating anti‑tumor activity and target engagement of mitochondrial carrier-directed small molecules in cancer‑relevant models. Most recently, the Company reported preliminary in vitro findings showing that selected MITOLINE™‑derived small‑molecule candidates reduced key pro‑inflammatory markers in human immune cells, providing MitoCareX with an initial line of evidence that mitochondrial carrier modulation can deliver anti‑inflammatory benefit in human‑relevant systems. Together, these results support further in vivo validation and lead optimization across multiple inflammatory metabolic disease indications in markets projected to exceed
$120 billion by 2030. - Advancing a precision oncology and inflammation pipeline: Building on its core expertise in mitochondrial carriers, MitoCareX is progressing a pipeline focused on hard‑to‑treat resistant cancers, alongside additional programs in metabolic‑inflammatory diseases. Guided by MITOLINE, the Company is working toward preclinical candidate nominations and aims to translate its in silico and in vitro discoveries into development‑ready assets.
The Nexentis brand is intended to capture the Company’s focus on the “next” generation of mitochondrial medicines, enabled by a computational platform and rigorous disease biology. Management believes this sharpened identity has the potential to enhance strategic clarity, improve alignment with the Company’s R&D priorities, and support engagement with partners and potential collaborators across the biotech and pharmaceutical ecosystem.
About N2OFF Inc:
N2OFF owns
N2OFF also controls approximately
For more information, please visit www.n2off.com.
Forward-looking Statements:
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses how it to intends to build a diversified pipeline of first‑in‑class small‑molecule programs, while continuing to selectively manage its RTB solar energy investments as a non‑core, value‑optimizing asset base, how the Company is working toward preclinical candidate nominations and aims to translate its in silico and in vitro discoveries into development‑ready assets, its focus on the “next” generation of mitochondrial medicines, enabled by a computational platform and rigorous disease biology and the potential to enhance strategic clarity, improve alignment with the Company’s R&D priorities, and support engagement with partners and potential collaborators across the biotech and pharmaceutical ecosystem. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to known and unknown risks, uncertainties and other factors that may cause N2OFF’s and its subsidiaries’ actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause actual results, performance or achievements to differ materially from those anticipated in these forward-looking statements include, among other things, our market and other conditions, history of losses and needs for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms, or at all; uncertainties of cash flows and inability to meet working capital needs; the initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate development efforts; our ability to advance our product candidates into clinical trials or to successfully complete our preclinical studies or clinical trials; our receipt of regulatory approvals for our product candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of our product candidates; our ability to establish and maintain strategic partnerships and other corporate collaborations; the implementation of our business model and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual property rights of others; competitive companies, technologies and our industry; risks related to not satisfying the continued listing requirements of Nasdaq Capital Market; and statements as to the impact of the political and security situation in Israel on our business. More information on these risks, uncertainties and other factors is included from time to time in the “Risk Factors” section of N2OFF’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 31, 2025 and other public reports filed with the SEC. Except as otherwise required by law, we undertake no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. We are not responsible for the contents of third-party websites.
Investor Relations Contact:
Michal Efraty
michal@efraty.com
FAQ
What does the N2OFF to Nexentis rebranding mean for shareholders and the stock symbol NITO?
When did Nexentis complete the acquisition of MitoCareX and why is it material to NXTS investors?
What evidence does Nexentis cite for MITOLINE™ platform validation and near‑term goals for NXTS?
How will Nexentis manage its solar RTB business after the strategic pivot announced on February 25, 2026?
Which disease areas is Nexentis prioritizing with its MITOLINE™‑driven pipeline under the NXTS symbol?
What market opportunity does Nexentis reference for its inflammatory metabolic disease programs?
